Cargando…
Can the Antisecretory Factor Be Considered a New Therapy for the Short Bowel Syndrome?
BACKGROUND AND OBJECTIVE: The antisecretory factor (AF) exerts antisecretory and anti-inflammatory properties in the bowel. The aim of this study was to evaluate the effect of exogenous AF (Salovum) or cereals stimulating the endogenous AF (SPC-Flakes), given alone or in combination, in patients wit...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6537051/ https://www.ncbi.nlm.nih.gov/pubmed/31205420 http://dx.doi.org/10.1177/1178638819852061 |
_version_ | 1783421918297194496 |
---|---|
author | Viggiani, Maria Teresa Di Leo, Alfredo Barone, Michele |
author_facet | Viggiani, Maria Teresa Di Leo, Alfredo Barone, Michele |
author_sort | Viggiani, Maria Teresa |
collection | PubMed |
description | BACKGROUND AND OBJECTIVE: The antisecretory factor (AF) exerts antisecretory and anti-inflammatory properties in the bowel. The aim of this study was to evaluate the effect of exogenous AF (Salovum) or cereals stimulating the endogenous AF (SPC-Flakes), given alone or in combination, in patients with short bowel syndrome (SBS). METHODS: Patients received Salovum alone at T(0) -T(1), Salovum plus SPC-Flakes at T(1) -T(2), and SPC-Flakes alone at T(2) -T(3). At T(0) and T(3), water balance, weight, lean mass (FFM), total body water (TBW), extracellular water (ECW), and nutritional and inflammatory biochemical parameters were evaluated. The water balance was also measured at T(1), T(2), and 30 days (T(S)) from the end of treatment. RESULTS: Among the 7 patients enrolled, 2 discontinued treatment due to side effects and 1 was excluded after a cancer was diagnosed. Salovum alone or with SPC-Flakes did not improve the intestinal absorption in patients with SBS, while the administration of SPC-Flakes alone lead towards a trend of increased faecal volume. Weight, FFM, TBW, and ECW, as well as nutritional and inflammatory status, did not statistically change at the end of treatment (T(3)) as compared with T(0). At T(S) water balance was restored. CONCLUSION: The administration of exogenous AF or the stimulation of endogenous AF seems to be unable to offer an effective therapy in patients with SBS. On the contrary, their administration appears to aggravate fluid loss and induce side effects. |
format | Online Article Text |
id | pubmed-6537051 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | SAGE Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-65370512019-06-14 Can the Antisecretory Factor Be Considered a New Therapy for the Short Bowel Syndrome? Viggiani, Maria Teresa Di Leo, Alfredo Barone, Michele Nutr Metab Insights Case Report BACKGROUND AND OBJECTIVE: The antisecretory factor (AF) exerts antisecretory and anti-inflammatory properties in the bowel. The aim of this study was to evaluate the effect of exogenous AF (Salovum) or cereals stimulating the endogenous AF (SPC-Flakes), given alone or in combination, in patients with short bowel syndrome (SBS). METHODS: Patients received Salovum alone at T(0) -T(1), Salovum plus SPC-Flakes at T(1) -T(2), and SPC-Flakes alone at T(2) -T(3). At T(0) and T(3), water balance, weight, lean mass (FFM), total body water (TBW), extracellular water (ECW), and nutritional and inflammatory biochemical parameters were evaluated. The water balance was also measured at T(1), T(2), and 30 days (T(S)) from the end of treatment. RESULTS: Among the 7 patients enrolled, 2 discontinued treatment due to side effects and 1 was excluded after a cancer was diagnosed. Salovum alone or with SPC-Flakes did not improve the intestinal absorption in patients with SBS, while the administration of SPC-Flakes alone lead towards a trend of increased faecal volume. Weight, FFM, TBW, and ECW, as well as nutritional and inflammatory status, did not statistically change at the end of treatment (T(3)) as compared with T(0). At T(S) water balance was restored. CONCLUSION: The administration of exogenous AF or the stimulation of endogenous AF seems to be unable to offer an effective therapy in patients with SBS. On the contrary, their administration appears to aggravate fluid loss and induce side effects. SAGE Publications 2019-05-23 /pmc/articles/PMC6537051/ /pubmed/31205420 http://dx.doi.org/10.1177/1178638819852061 Text en © The Author(s) 2019 http://creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
spellingShingle | Case Report Viggiani, Maria Teresa Di Leo, Alfredo Barone, Michele Can the Antisecretory Factor Be Considered a New Therapy for the Short Bowel Syndrome? |
title | Can the Antisecretory Factor Be Considered a New Therapy for the
Short Bowel Syndrome? |
title_full | Can the Antisecretory Factor Be Considered a New Therapy for the
Short Bowel Syndrome? |
title_fullStr | Can the Antisecretory Factor Be Considered a New Therapy for the
Short Bowel Syndrome? |
title_full_unstemmed | Can the Antisecretory Factor Be Considered a New Therapy for the
Short Bowel Syndrome? |
title_short | Can the Antisecretory Factor Be Considered a New Therapy for the
Short Bowel Syndrome? |
title_sort | can the antisecretory factor be considered a new therapy for the
short bowel syndrome? |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6537051/ https://www.ncbi.nlm.nih.gov/pubmed/31205420 http://dx.doi.org/10.1177/1178638819852061 |
work_keys_str_mv | AT viggianimariateresa cantheantisecretoryfactorbeconsideredanewtherapyfortheshortbowelsyndrome AT dileoalfredo cantheantisecretoryfactorbeconsideredanewtherapyfortheshortbowelsyndrome AT baronemichele cantheantisecretoryfactorbeconsideredanewtherapyfortheshortbowelsyndrome |